Splash celebration glitter
Pharma

$200M in 5 weeks: Behind RevMed's 'eye-popping' Rasonque debut

Generating $198 million in its first five weeks, Revolution Medicines’ RAS inhibitor daraxonrasib is living up to its much-hyped potential.
Fraiser Kansteiner Nov 5, 2026 11:11am
Asking More of Science How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care

Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care

Brought to you by Daiichi Sankyo, Inc.
Tribeca campus Kings Cross London Kings Cross Knowledge Quarter

Moderna to move HQ across London to buzzy life-sci campus

Nov 9, 2026 8:30am
Image of Zepbound injectible with Eli Lilly oral weight loss drugs
Favicon Fierce Healthcare

Hims & Hers partners with Eli Lilly to sell Zepbound, Foundayo

Nov 6, 2026 4:30pm
CMSgov website with a phone that has the CMS logo in front of it

CMS locks in Medicare drug price negotiations for the long haul

Nov 6, 2026 4:24pm
Jeremy Pope in ViiVs PrEP Wisdom

Jeremy Pope joins ViiV in spreading 'PrEP Wisdom'

Nov 6, 2026 1:44pm
More News

Moderna's COVID vax leads strong Q3 beat

Nov 6, 2026 12:00pm

The Oral GLP-1 Tracker: Foundayo's record, Wegovy pill's rebound

Nov 6, 2026 11:30am

Regulatory tracker: J&J's Rybrevant Faspro pushes into new niche

Nov 6, 2026 10:45am

Novartis confirms several new tumor cases in Zolgensma patients

Nov 6, 2026 9:59am